share_log

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

阿里拉姆制藥 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 08:25

Moomoo AI 已提取核心訊息

Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.
Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year due to lower collaboration revenues, while net product revenues grew 34% to $420.1 million driven by strong AMVUTTRA sales. The company posted a net loss of $111.6 million compared to net income of $147.8 million in Q3 2023.Product revenue growth was led by AMVUTTRA at $258.6 million (+74% YoY) and GIVLAARI at $71.0 million (+31% YoY), while ONPATTRO declined 38% to $50.3 million due to patient switches to AMVUTTRA. Operating expenses increased 8% to $577.8 million reflecting continued investment in R&D and commercial infrastructure.The company maintained a strong balance sheet with $2.78 billion in cash and investments. Management highlighted positive clinical trial results for vutrisiran in ATTR amyloidosis with cardiomyopathy and regulatory submissions to FDA and EMA. The company continues to advance its RNAi therapeutic pipeline while building global commercial capabilities.
阿里拉姆制藥報告2024年第三季度總營業收入爲50090萬，同比下降33%，主要由於合作收入降低，而淨產品收入增長34%，達42010萬，受益於AMVUTTRA銷售強勁。公司報告淨虧損爲11160萬，而2023年第三季度的凈利潤爲14780萬。產品收入的增長主要來自AMVUTTRA，收入達25860萬，同比增長74%；GIVLAARI收入爲7100萬，同比增長31%；而ONPATTRO由於患者轉向使用AMVUTTRA，收入下降38%，降至5030萬。營業費用增長8%，達57780萬，反映出對研發和商業製造行業的持續投資。公司保持強勁的資產負債表，現金和投資達到27.8億。管理層強調了vutrisiran在伴有心肌病的ATTR澱粉樣變的積極臨牀試驗結果，以及向FDA和EMA的監管提交。公司繼續推進其RNAi治療管道，同時構建全球商業能力。
阿里拉姆制藥報告2024年第三季度總營業收入爲50090萬，同比下降33%，主要由於合作收入降低，而淨產品收入增長34%，達42010萬，受益於AMVUTTRA銷售強勁。公司報告淨虧損爲11160萬，而2023年第三季度的凈利潤爲14780萬。產品收入的增長主要來自AMVUTTRA，收入達25860萬，同比增長74%；GIVLAARI收入爲7100萬，同比增長31%；而ONPATTRO由於患者轉向使用AMVUTTRA，收入下降38%，降至5030萬。營業費用增長8%，達57780萬，反映出對研發和商業製造行業的持續投資。公司保持強勁的資產負債表，現金和投資達到27.8億。管理層強調了vutrisiran在伴有心肌病的ATTR澱粉樣變的積極臨牀試驗結果，以及向FDA和EMA的監管提交。公司繼續推進其RNAi治療管道，同時構建全球商業能力。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！